Inactive Instrument

Orgenesis Inc Stock Other OTC

US68619K1051

Medical Equipment, Supplies & Distribution

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâ€™s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâ€™s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	983K 849K 798K 725K 1.36M 93.98M 1.39M 9.35M 3.65M 47.06M 3.69M 3.61M 156M	P/E 2023	-0.26x	P/E 2024	-0.17x
Enterprise Value	19.16M 16.55M 15.55M 14.15M 26.59M 1.83B 27.03M 182M 71.25M 918M 71.95M 70.39M 3.05B	EV / Sales 2023	71.2x	EV / Sales 2024	27x
Free-Float	52.06%	Yield 2023 *	-	Yield 2024	-

03-26	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03-25	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI
03-25	Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc..	CI
03-13	Orgenesis Inc. Announces Board Appointments, Effective March 10, 2026	CI
03-13	Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026	CI
25-08-25	Orgenesis Inc. Announces Resignation of Director Ashish Nanda, Effective August 21, 2025	CI
25-08-19	Orgenesis Inc. Announces Resignation of Victor Miller as Chief Financial Officer	CI
25-08-19	Orgenesis Inc. Announces Executive and Board Changes	CI
25-03-05	Orgenesis Inc. completed the acquisition of Certain assets of Neurocords LLC for $5.7 million.	CI
25-01-21	Orgenesis Inc. announced that it expects to receive $5 million in funding	CI
24-12-27	Orgenesis Inc. Announces Resignation of Jagannathan Bhalaji as A Director	CI
24-11-13	Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	CI
24-11-13	Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

03-26	Orgenesis : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
24-11-13	Orgenesis Provides Third Quarter 2024 Business Update	AQ
24-10-21	Orgenesis Commences Trading on OTCQX® Best Market	AQ
24-09-23	Orgenesis Announces Reverse Stock Split	AQ
24-08-29	Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia	AQ

Manager	Title	Age	Since
Sarah Ferber CTO	Chief Tech/Sci/R&D Officer	72	2012-02-01
Vered Caplan CEO	Chief Executive Officer	57	2013-12-23
Douglas Karriker DFI	Director of Finance/CFO	51	2026-03-09

Director	Title	Age	Since
Vered Caplan CHM	Chairman	57	2014-08-13
Itzhak Vider BRD	Director/Board Member	64	2024-07-07
Adam Pelavin BRD	Director/Board Member	47	2024-10-27

Orgenesis Inc Stock Other OTC

Stocks

US68619K1051

Medical Equipment, Supplies & Distribution

Valuation: Orgenesis Inc

Latest news : Orgenesis Inc

Press Releases: Orgenesis Inc

Quotes and Performance

Managers and Directors: Orgenesis Inc

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORGENESIS INC	+17.76%	+8.82%	-	-	3.43M
ABBOTT LABORATORIES	-0.02%	+3.19%	-15.56%	+6.43%	193B
MEDTRONIC PLC	+0.76%	+4.72%	-1.88%	+11.89%	117B
CENCORA, INC.	+1.23%	-2.07%	+7.17%	+70.56%	59.89B
HOYA CORPORATION	-0.92%	+0.57%	+34.56%	+70.98%	56.01B
BECTON, DICKINSON AND COMPANY	+0.79%	+3.70%	-6.40%	-33.73%	49.96B
DEXCOM, INC.	-1.89%	+5.90%	+10.87%	-19.26%	33.87B
MEDLINE INC.	+0.45%	+1.45%	-	-	31.36B
TERUMO CORPORATION	-1.96%	+1.73%	-6.04%	+27.56%	24.77B
WEST PHARMACEUTICAL SERVICES, INC.	+0.94%	-1.31%	+41.93%	-12.09%	24.59B
Average	+1.41%	+3.57%	+8.08%	+15.29%	65.53B
Weighted average by Cap.	-0.51%	+3.34%	+0.14%	+15.90%

	2023	2024
Net sales	530K 458K 430K 391K 735K 50.68M 748K 5.04M 1.97M 25.38M 1.99M 1.95M 84.34M	1.03M 894K 840K 764K 1.44M 98.97M 1.46M 9.84M 3.85M 49.56M 3.89M 3.8M 165M
Net income	-55.36M -47.82M -44.93M -40.86M -76.83M -5.29B -78.09M -526M -206M -2.65B -208M -203M -8.81B	-48.16M -41.6M -39.09M -35.55M -66.84M -4.61B -67.94M -458M -179M -2.31B -181M -177M -7.66B
Net Debt	21.78M 18.81M 17.68M 16.08M 30.23M 2.08B 30.73M 207M 81M 1.04B 81.79M 80.01M 3.47B	18.18M 15.7M 14.76M 13.42M 25.23M 1.74B 25.65M 173M 67.6M 871M 68.26M 66.78M 2.89B